<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: CD44 is considered as 'a' <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> associated gene, despite the fact that it is an umbrella term for a group of molecules produced from a single gene by alternative splicing </plain></SENT>
<SENT sid="1" pm="."><plain>However, little consideration is given to the above in the literature of colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> as well as other <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types, leading to <z:hpo ids='HP_0001289'>confusion</z:hpo> and contradictory results about its possible role in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We compared the CD44 alternative splice pattern (ASP) of three genetically different human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines (HT25, HT29, HCT116) using a series of PCR reactions and next- generation sequencing method, as well as identified a colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> specific CD44 ASP </plain></SENT>
<SENT sid="3" pm="."><plain>This ASP was further investigated in terms of its qualitative and quantitative stability in our experimental iso- and xenograft mouse models for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> progression </plain></SENT>
<SENT sid="4" pm="."><plain>A complex preclinical experimental set-up was established to separately test the different steps of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> and the role of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> microenvironment, respectively, focusing on the role of 'CD44' in this process </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We managed to present a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific CD44 ASP, which remained unchanged from cell lines throughout <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> formation and metastatic progression </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, we report a unique roster of <z:hpo ids='HP_0000001'>all</z:hpo> expressed CD44 variant isoforms characteristic to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, on quantitative assessment of the variable exons v3 and v6, higher co-expression levels were found to be characteristic to metastatically potent <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Particular CD44 variant isoforms seem to act as "<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> genes" via <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> microenvironment-driven shifts in v3 and v6 expressions </plain></SENT>
<SENT sid="9" pm="."><plain>However, this function may just affect a minority of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> subclones </plain></SENT>
<SENT sid="10" pm="."><plain>This fact and the huge potential number of different CD44 splice variants that can contain v3 and v6 domains can explain <z:e sem="disease" ids="C0233643" disease_type="Mental or Behavioral Dysfunction" abbrv="">incoherence</z:e> of clinical studies regarding functional asessment of CD44 variants, as well as diminish the chances of using CD44 variants for predictive purpose </plain></SENT>
</text></document>